CD274 and non-small cell lung carcinoma: Immune checkpoint blockade (ICB), e.g., anti-programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1), has emerged as a promising treatment choice against advanced NSCLC [5–7].